ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results

April 21, 2022

From ImmunoGen Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 14, 2022

Gainers

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 01, 2022

From ImmunoGen, Inc.

Via Business Wire

Why Are ImmunoGen Shares Trading Lower Today ↗

March 21, 2022

ImmunoGen Inc (NASDAQ: IMGN)

Via Benzinga

ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

March 31, 2022

From ImmunoGen, Inc.

Via Business Wire

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

March 29, 2022

From ImmunoGen, Inc.

Via Business Wire

75 Biggest Movers From Yesterday ↗

March 22, 2022

Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 21, 2022

Gainers

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 21, 2022

During Monday's session, 39 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap to set a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2022 ↗

March 21, 2022

Upgrades According to B. Riley Securities, the prior rating for BRT Apartments Corp (NYSE:BRT) was changed from Neutral to Buy. BRT Apartments earned $0.41 in the fourth quarter,...

Via Benzinga

46 Stocks Moving In Monday's Mid-Day Session ↗

March 21, 2022

Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) climbed 369% to $7.32 as the company received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 21, 2022

Gainers Corbus Pharmaceuticals (NASDAQ:CRBP) shares increased by 20.3% to $0.4 during Monday's pre-market session. The market value of their outstanding shares is at $49.7 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

March 21, 2022

Welcome back, investor! We're getting right into the thick of it with a look at the biggest pre-market stock movers for Monday!

Via InvestorPlace

28 Stocks Moving in Monday's Pre-Market Session ↗

March 21, 2022

Gainers BitNile Holdings, Inc. (NYSE: NILE) rose 61.1% to $0.90 in pre-market trading. BitNile's TurnOnGreen resumed expansion of its electric vehicle charging network and e-...

Via Benzinga

ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting

March 19, 2022

From ImmunoGen, Inc.

Via Business Wire

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision ↗

February 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To...

Via Benzinga

Immunogen: Q4 Earnings Insights ↗

February 25, 2022

Immunogen (NASDAQ:IMGN) reported its Q4 earnings results on Friday, February 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

ImmunoGen Reports Recent Progress and 2021 Financial Results

February 25, 2022

From ImmunoGen Inc.

Via Business Wire

Earnings Scheduled For February 25, 2022 ↗

February 25, 2022

Companies Reporting Before The Bell • ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million. •...

Via Benzinga

Earnings Outlook For Immunogen ↗

February 24, 2022

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference

February 23, 2022

From ImmunoGen, Inc.

Via Business Wire

Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B ↗

February 15, 2022

ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and...

Via Benzinga

ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion

February 15, 2022

From ImmunoGen Inc.

Via Business Wire

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results

February 10, 2022

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference

February 04, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 01, 2022

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs

January 31, 2022

From ImmunoGen Inc.

Via Business Wire

Sutro Biopharma Collapses; Why One Analyst Remains Bullish On Its Chances In Cancer ↗

January 06, 2022

Sutro Biopharma could still find a place for itself in ovarian cancer treatment.

Via Investor's Business Daily

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.